https://www.onclive.com/view/pelabresib-ruxolitinib-data-underscore-need-for-novel-end-points-in-myelofibrosis-trials
https://firstwordpharma.com/story/5876742
A few exec's over at Novartis sweating their $2.9 acquisition.
MANIFEST-2 hit the primary endpoint of spleen volume response but missed the secondary endpoint of total symptom score response.
MANIFEST-2 presented at the 2024 ASCO Annual Meeting showed that patients with myelofibrosis who received frontline pelabresib (CPI-0610) plus ruxolitinib (Jakafi; n = 214) experienced an SVR35 rate of 65.9% at week 24 compared with 35.2% for those given ruxolitinib plus placebo (n = 216). Notably, updated data showed that in patients who experienced an SVR35 at any time, 13.4% of patients in the experimental arm lost that response vs 27.8% of patients in the placebo arm.
Additionally, the TSS50 rates at week 24 were 52.3% for pelabresib plus ruxolitinib vs 46.3% for placebo plus ruxolitinib, translating to a numerical improvement that was not statistically significant (difference, 6.0%; 95% CI, –3.5% to 15.5%; nominal P = .216).
Notably, 40.2% of patients in the pelabresib arm experienced both SVR35 and TSS50 at week 24 compared with 18.5% of patients in the placebo arm.
Query over safety.
There was a concern over an increased risk of leukemic transformation and increased proportion of patients with blast transformation. If we look at pelabresib plus ruxolitinib, 2.4% of patients [in the combination arm] vs 0.5% of patients on placebo plus ruxolitinib [experienced blast phase progression].
I like this from Mr Gerds
"We have drugs that are good at making patients’ symptoms better; however, we need are drugs that truly modify the disease course in a meaningful way,” Gerds explained."
- Forums
- ASX - By Stock
- SNT
- SNT - General Discussions
SNT - General Discussions, page-90
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.4¢ |
Change
0.002(3.85%) |
Mkt cap ! $74.14M |
Open | High | Low | Value | Volume |
5.5¢ | 5.8¢ | 5.4¢ | $227.9K | 4.092M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 168534 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 18534 | 0.054 |
2 | 75406 | 0.053 |
2 | 203845 | 0.052 |
4 | 727584 | 0.051 |
4 | 677500 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 20000 | 1 |
0.058 | 194700 | 4 |
0.059 | 416966 | 2 |
0.060 | 978947 | 8 |
0.062 | 130000 | 1 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online